NEW Q2. Mark Johnson is controller for a Pharmaceutical company. During the company's midyear review, Johnson notes that the company's R&D expenditures are already $3.0 billion, ņearly 40% above the midyear target. In a meeting with the CFO later that day, Johnsons delivers the bad news to the CFO, Pauline Stewart. Stewart was shocked and outraged that the R&D spending had gotten out of control. Stewart wasn't any more understanding when Johnson revealed that the excess cost was entirely related to research and development of a new drug, Lucexx, which was expected to go to market next year. The new drug would result in large profits for the company, if the product could be approved

FINANCIAL ACCOUNTING
10th Edition
ISBN:9781259964947
Author:Libby
Publisher:Libby
Chapter1: Financial Statements And Business Decisions
Section: Chapter Questions
Problem 1Q
icon
Related questions
icon
Concept explainers
Question
NEW
Q2. Mark Johnson is controller for a Pharmaceutical company. During the
company's midyear review, Johnson notes that the company's R&D
expenditures are already $3.0 billion, nearly 40% above the midyear
target. In a meeting with the CFO later that day, Johnsons delivers the
bad news to the CFO, Pauline Stewart. Stewart was shocked and
outraged that the R&D spending had gotten out of control. Stewart wasn't
any more understanding when Johnson revealed that the excess cost
was entirely related to research and development of a new drug, Lucexx,
which was expected to go to market next year. The new drug would
result in large profits for the company, if the product could be approved
by year-end. Johnson came up with the following ideas for making the
third-quarter budgeted targets:Sell off rights to the drug, Martek. The
company had not planned on doing this because, under current market
conditions, it would get less than fair value. It would, however, result in a
onetime revenue that could offset the budget shortfall. The patent on
Martek is about to expire, after which any competitor can make the drug.
On balance, the results on the company of this action are:
A.An overall positive effect on short-term profits, while not affecting expected long-term profits
B.An overall negative effect on short-term profits, while not affecting expected long-term profits
OC.An overall positive effect on short-term profits, while diminishing expected long-term profits
D.No predictable effect on short-term profits
Transcribed Image Text:NEW Q2. Mark Johnson is controller for a Pharmaceutical company. During the company's midyear review, Johnson notes that the company's R&D expenditures are already $3.0 billion, nearly 40% above the midyear target. In a meeting with the CFO later that day, Johnsons delivers the bad news to the CFO, Pauline Stewart. Stewart was shocked and outraged that the R&D spending had gotten out of control. Stewart wasn't any more understanding when Johnson revealed that the excess cost was entirely related to research and development of a new drug, Lucexx, which was expected to go to market next year. The new drug would result in large profits for the company, if the product could be approved by year-end. Johnson came up with the following ideas for making the third-quarter budgeted targets:Sell off rights to the drug, Martek. The company had not planned on doing this because, under current market conditions, it would get less than fair value. It would, however, result in a onetime revenue that could offset the budget shortfall. The patent on Martek is about to expire, after which any competitor can make the drug. On balance, the results on the company of this action are: A.An overall positive effect on short-term profits, while not affecting expected long-term profits B.An overall negative effect on short-term profits, while not affecting expected long-term profits OC.An overall positive effect on short-term profits, while diminishing expected long-term profits D.No predictable effect on short-term profits
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 2 steps

Blurred answer
Knowledge Booster
Cost volume profit (CVP) analysis
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
FINANCIAL ACCOUNTING
FINANCIAL ACCOUNTING
Accounting
ISBN:
9781259964947
Author:
Libby
Publisher:
MCG
Accounting
Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,
Accounting Information Systems
Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,
Horngren's Cost Accounting: A Managerial Emphasis…
Horngren's Cost Accounting: A Managerial Emphasis…
Accounting
ISBN:
9780134475585
Author:
Srikant M. Datar, Madhav V. Rajan
Publisher:
PEARSON
Intermediate Accounting
Intermediate Accounting
Accounting
ISBN:
9781259722660
Author:
J. David Spiceland, Mark W. Nelson, Wayne M Thomas
Publisher:
McGraw-Hill Education
Financial and Managerial Accounting
Financial and Managerial Accounting
Accounting
ISBN:
9781259726705
Author:
John J Wild, Ken W. Shaw, Barbara Chiappetta Fundamental Accounting Principles
Publisher:
McGraw-Hill Education